Browse Studies — Arctuva

Phase 3

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid…

Refractory Differentiated Thyroid Gland Carcinoma

Estimated

~$10 – $7,500

ECOG-ACRIN Cancer Research GroupNCT06475989

Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for …

Differentiated Thyroid Gland CarcinomaThyroid Gland Follicular CarcinomaThyroid Gland Papillary Carcinoma

Estimated

~$10 – $750

Mayo ClinicNCT05575440

Phase 2

A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer

This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment wi…

Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular Carcinoma+18 more

Estimated

Observational

Personalized Cancer Support for Young Adults

This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality inform…

Differentiated Thyroid Gland CarcinomaMalignant Testicular NeoplasmMelanoma+2 more

Estimated

~$10 – $6,250

University of Michigan Rogel Cancer CenterNCT07529080